Soligenix Reports Positive Phase 2 Trial Results for SGX945
ByAinvest
Thursday, Dec 18, 2025 7:50 am ET1min read
SNGX--
Soligenix, a biopharmaceutical company, reported positive results from a phase 2 trial of SGX945, a therapeutic candidate for inflammatory diseases. The trial showed SGX945 to be safe and effective in treating inflammatory diseases, with no serious adverse events reported. Soligenix's other development programs include RiVax, a ricin toxin vaccine candidate, and CiVax, a COVID-19 vaccine candidate.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet